ALTEOGEN Past Earnings Performance

Past criteria checks 0/6

ALTEOGEN has been growing earnings at an average annual rate of 15.3%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 24.9% per year.

Key information

15.3%

Earnings growth rate

15.6%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate24.9%
Return on equity-1.9%
Net Margin-3.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

May 25
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

Recent updates

ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

May 25
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Feb 29
ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability

Apr 13
ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability

Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Feb 18
Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

Dec 27
Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

Revenue & Expenses Breakdown

How ALTEOGEN makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A196170 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2474,375-2,90612,58423,855
30 Jun 2490,788-1,28212,70428,641
31 Mar 24121,08725,54213,95523,635
31 Dec 2396,523-3,37214,46825,306
30 Sep 2385,0366,45914,42121,286
30 Jun 2369,1547,86515,08317,695
31 Mar 2332,199-21,79814,92722,559
31 Dec 2228,806-8,14614,23418,660
30 Sep 2232,2921,36714,41212,422
30 Jun 2233,065-22315,1074,731
31 Mar 2233,807-1,24322,7091,165
31 Dec 2138,746-6,27512,7137,480
30 Sep 2129,498-38,97112,25114,481
30 Jun 2137,316-26,97512,13414,481
31 Mar 2144,433-17,7483,17915,350
31 Dec 2042,426-15,82210,5377,691
30 Sep 2051,93515,4249,5136,308
30 Jun 2043,4209,0407,8866,308
31 Mar 2035,2425,0016,9665,566
31 Dec 1929,229-7056,4186,457
30 Sep 1918,012-7,9005,6475,671
30 Jun 1915,796-8,5746,1105,671
31 Mar 1913,473-8,0783,9786,718
31 Dec 1813,703-6,8723,3555,962
30 Sep 1813,079-11,7762,6157,983
30 Jun 1812,610-9,9457947,983
31 Mar 1811,788-10,3321,7906,394
31 Dec 1712,104-7,4492,3164,654
30 Sep 1711,815-2,8372,3053,631
30 Jun 1711,567-2,8712,3143,631
31 Mar 1710,569-1,9612,2573,765
31 Dec 166,844-3,5871,8793,976
30 Sep 166,088-1,4811,6033,323
30 Jun 164,213-2018913,323
31 Mar 163,634-1365992,719
31 Dec 154,7271,2081,3331,947
30 Sep 154,5853371,3751,982
30 Jun 155,6863201,2071,982
31 Mar 156,8741,2091,4111,906
31 Dec 147,0439311,2851,837
30 Sep 146,7531,1581,2941,534
30 Jun 146,2571,2249911,791
31 Mar 146,0031,4347471,692
31 Dec 135,5271,6061,1591,043

Quality Earnings: A196170 is currently unprofitable.

Growing Profit Margin: A196170 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A196170 is unprofitable, but has reduced losses over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare A196170's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A196170 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A196170 has a negative Return on Equity (-1.91%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies